Skip to Main content Skip to Navigation
Journal articles

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Philippe Merle Jean-Frederic Blanc Jean-Marc Phélip Gilles Pelletier Jean-Pierre Bronowicki Yann Touchefeu Georges Pageaux 1, 2 Rene Gerolami 3, 4 François Habersetzer Eric Nguyen-Khac Andrea Casadei-Gardini Ivan Borbath Albert Tran Henning Wege Amr Shafik Saad Massimo Colombo Armand Abergel Carine Richou Imam Waked Nelson Yee Audrey Molé Pierre Attali Julie Le Boulicaut Bérangère Vasseur Driffa Moussata Jean-Didier Grangé Vlad Ratziu Faiza Khemissa-Akouz Hélène Régnault Barbara Dauvois Jean-Pierre Zarski Isabelle Ollivier-Hourmand Sylvain Manfredi Marilyne Debette-Gratien 5 Alice Gangloff 6 Thierry Fontanges Aurore Baron Mohamed Bouattour Julie Vincent Wolfgang Sieghart Andrea Maieron Marc Peeters Jean Delwaide Luc Lasser Thomas Berg Michael Schultheiß Alexander Zipprich Joerg Trojan Ursula Ehmer Gabriele Luppi Luc Luca Stefano Tamberi Domenico Amoroso Oscar Alabiso Angela Buonadonna Pierluigi Toniutto Emiliano Tamburini Antonio Cubillo Andrés Muñoz Carmen Guillén Gloria Sánchez Hermini Manzano Victor Navarro Inmaculada Ales Bartomeu Massuti Magdolna Dank György Bodoky Zsuzsanna Kahan Zsolt Horváth Nashat Gabrail Howard Ozer Christos Galanopoulos Ralph Hauke Moses Raj Hakan Harputluoglu Alper Sevinc Erdem Goker Ahmet Coker Suayib Yalcin Muhammet Ali Ozlem Ata Ilkay Tugba Mohammed El Kassas Amr Abdel Imam Wakid Sameh Shamaa Nasr El Lahlouby Hanaa Kohail Jawad Makarem Issam Chehade Fadi Farhat Carlos Lopez Miguel Marín
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-02262527
Contributor : Isabelle Combe <>
Submitted on : Friday, August 2, 2019 - 4:36:21 PM
Last modification on : Wednesday, August 19, 2020 - 12:06:55 PM

Links full text

Identifiers

Citation

Philippe Merle, Jean-Frederic Blanc, Jean-Marc Phélip, Gilles Pelletier, Jean-Pierre Bronowicki, et al.. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. The Lancet Gastroenterology and Hepatology, Elsevier, 2019, 4 (6), pp.454-465. ⟨10.1016/S2468-1253(19)30040-8⟩. ⟨hal-02262527⟩

Share

Metrics

Record views

83